Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather M Jackson

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Cancer Immunology, Immunotherapy : CII|June 24, 2011
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™Theo Nicholaou, Weisan Chen, Ian D Davis, et al.
Cancer Research|January 30, 2009
A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine designLisa M Ebert, Yu Chih Liu, Craig S Clements, et al.
Plos One|September 13, 2012
A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigenRona Y Zhao, Nicole A Mifsud, Kun Xiao, et al.
Journal for Immunotherapy of Cancer|April 23, 2020
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanomaJonathan S Cebon, Martin Gore, John F Thompson, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Cancer Immunology, Immunotherapy : CII|June 24, 2011
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™Theo Nicholaou, Weisan Chen, Ian D Davis, et al.
Cancer Research|January 30, 2009
A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine designLisa M Ebert, Yu Chih Liu, Craig S Clements, et al.
Plos One|September 13, 2012
A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigenRona Y Zhao, Nicole A Mifsud, Kun Xiao, et al.
Journal for Immunotherapy of Cancer|April 23, 2020
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanomaJonathan S Cebon, Martin Gore, John F Thompson, et al.
Pageof 2